Iterum Therapeutics (NASDAQ:ITRM) and Veru (NASDAQ:VERU) Head-To-Head Contrast

Veru (NASDAQ:VERU) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Volatility and Risk

Veru has a beta of -1.2, suggesting that its stock price is 220% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500.

Earnings and Valuation

This table compares Veru and Iterum Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89 million	2.22	-$22.73 million	($0.69)	-3.18
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04

Veru has higher revenue and earnings than Iterum Therapeutics. Veru is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Veru and Iterum Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1	0	3	0	2.50
Iterum Therapeutics	1	2	0	0	1.67

Veru currently has a consensus target price of $24.50, indicating a potential upside of 1,016.17%. Given Veru’s stronger consensus rating and higher possible upside, equities analysts clearly believe Veru is more favorable than Iterum Therapeutics.

Institutional and Insider Ownership

47.2% of Veru shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Veru and Iterum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Iterum Therapeutics	N/A	N/A	-65.54%

Summary

Veru beats Iterum Therapeutics on 9 of the 13 factors compared between the two stocks.

About Veru

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.